Drug Search Results
Using advanced filters...
Advanced Search [+]

Sulfisoxazole

Alternative Names: sulfisoxazole, sosol, soxazole, sulsoxin, sulfalar
Latest Update: 2021-04-06
Latest Update Note: Clinical Trial Update

Product Description

oral antibiotic (Sourced from: https://clinicaltrials.gov/ct2/history/NCT02099240?V_4=View)

Mechanisms of Action: Dihydropteroate synthase Inhibitor,CYP2C9 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Dominican Republic | Egypt | Pakistan | Taiwan | Turkey | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Julio Ramirez
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Pneumonia, Pneumocystis

Phase 1: Osteomyelitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MICU-PCP

P4

Unknown status

Pneumonia, Pneumocystis

2022-06-20

PRESTO:Osteo

P1

Terminated

Osteomyelitis

2018-11-07

Recent News Events

Date

Type

Title